Table 2.
Spectrum of activity of new antibiotics for difficult-to-treat resistance (DTR) gram-negative bacteria (GNB).
| ESBL | CRE-KPC | CRE-OXA48 | CRE-MBL | DTR P. Aeruginosa | DTR Acinetobacter | |
|---|---|---|---|---|---|---|
| BL/BLI Combination | ||||||
| • Ceftolozane/Tazobactam |
|
|
|
|
1
|
|
| • Ceftazidime-Avibactam |
|
|
|
|
|
|
| • Imipenem-Relebactam |
|
|
2
|
|
3
|
|
| • Meropenem-Vaborbactam |
|
|
|
|
|
|
| • Aztreonam-Avibactam |
|
|
|
4
|
5
|
|
| • Cefepime/Zidebactam |
|
|
|
|
|
|
| • Meropenem/Nacubactam |
|
|
|
|
|
|
| • Ceftaroline/Avibactam |
|
|
|
|
|
|
| Novel Cephalosporine | ||||||
| • Cefiderocol |
|
|
|
|
|
|
| Novel Amynoglicoside | ||||||
| • Plazomicin |
|
|
6
|
7
|
8
|
8
|
| Novel Tetracycline | ||||||
| • Eravacyclin |
|
|
|
|
|
|
| • Murepavadin |
|
|
|
|
|
|
No activity or intrinsic or acquired resistance. Activity. Abbreviations: BL/BLI, β-lactam/β-lactamase Inhibitor CRE, carbapenem resistant Enterobacteriacae; ESBL, extended-spectrum beta-lactamase; MBLs, metallo-β-lactamases; OMPTA, outer membrane protein targeting antibiotics. 1. Decreased activity for carbapenemase-producing strains of CR P. aeruginosa; 2. Very weak activity; 3. Not have activity against MBL; 4. Reduced activity against certain NDM Escherichia coli isolates; 5. Activity comparable to aztreonam alone; 6. Activity against OXA-type CREs but increased resistance is observed; 7. Not active against many NDMs; 8. Activity toward P. aeruginosa and A. baumannii is overall comparable to existing aminoglycosides (tobramycin, amikacin, gentamicin).